Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

British journal of clinical pharmacology - 1 May 2008

Baldwin R Michael, Ohlsson Staffan, Pedersen Rasmus Steen, Mwinyi Jessica, Ingelman-Sundberg Magnus, Eliasson Erik, Bertilsson Leif

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The only existing study of CYP2C19*17-associated alterations in drug pharmacokinetics was retrospective and compared probe drug metabolic ratios. The CYP2C19*17 allele had been associated with a two- and fourfold decrease in omeprazole and S/R-mephenytoin metabolic ratios. WHAT THIS STUDY ADDS: This study characterized the single-dose pharmacokinetics of omeprazole, along...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C19

Share to Mixed Function Oxygenases

Share to Omeprazole

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 18294333
DOI: 10.1111/j.1365-2125.2008.03104.x
PMCID: PMC2432489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.PMID 18294333Read ↗

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.Semantic proximity Read ↗

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.Semantic proximity Read ↗

Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Semantic proximity Read ↗

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.Semantic proximity Read ↗

Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele.Semantic proximity Read ↗

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.Semantic proximity Read ↗

Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.Semantic proximity Read ↗

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.Semantic proximity Read ↗

Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.